How does the human brain connectome reorganize in Alzheimer's disease, and what are the vulnerable hub regions that drive network-wide disintegration? Does connectome breakdown precede or follow amyloid/tau pathology, and can graph-theoretic measures of connectome integrity serve as early biomarkers of neurodegeneration?
Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Amyloid-beta Plaques Phospholipid Ligands"]
B["TREM2 Receptor Ligand Binding"]
C["TYROBP/DAP12 ITAM Phosphorylation"]
D["SYK Kinase Activation"]
E["PLCG2 IP3 + DAG Generation"]
F["Ca2+ Release Cytoskeletal Remodeling"]
G["Microglial Phagocytosis Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for Microglial TREM2 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMIDValidation: 0%5 supporting / 4 opposing
✓For(5)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
1
1
MECH 7CLIN 1GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 loss-of-function variants increase AD risk 2…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-18 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses: Connectome Preservation in Alzheimer's Disease
Hypothesis 1: Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
Description: Transcranial focused ultrasound (tFUS) can transiently open the blood-brain barrier in AD patients, enabling targeted delivery of anti-amyloid antibodies specifically to hub regions showing highest connectivity burden. This approach exploits the spatial correlation between hub vulnerability and amyloid accumulation to concentrate therapeutic effect where it is most needed.
Target: Blood-brain ba
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Connectome Preservation Hypotheses in Alzheimer's Disease
Overview Assessment
These seven hypotheses collectively represent a sophisticated network-level approach to AD therapeutics, moving beyond the amyloid-centric paradigm. However, they share several systemic weaknesses: (1) heavy reliance on correlative rather than causal evidence for hub vulnerability, (2) limited validation in human tissue/clinical data, and (3) insufficient consideration of compensatory mechanisms and stage-dependent effects. I will evaluate each hypothesis individually before providing
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Expert Evaluation: Connectome Preservation Hypotheses in Alzheimer's Disease
Drug Development Reality Check
I will evaluate each hypothesis against practical criteria: target tractability, chemical matter availability, competitive positioning, safety profile, and realistic development pathways. This analysis will identify which hypotheses merit continued investment and which require fundamental reconceptualization.
Hypothesis 1: Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
Target Druggability and Chemical Matter
**Transcranial Focused
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we administer a selective TREM2 agonist (anti-TREM2 agonistic antibody at 10mg/kg, weekly ip) to 6-month-old 5xFAD mice for 8 weeks, THEN we will observe a significant reduction in cortical synaptic density (measured by PSD-95+ vGLUT1 colocalization via confocal microscopy) compared to vehicle-treated 5xFAD controls, indicating enhanced pruning regulation.
pendingconf: 0.65
Expected outcome: ≥20% reduction in excitatory synapse density (PSD-95/vGLUT1 puncta) in cortical layer 5 neurons in the agonist-treated group versus vehicle controls
Falsified by: No significant difference in synaptic density between TREM2 agonist and vehicle groups (p>0.05) OR paradoxical increase in synapse number, indicating impaired rather than enhanced pruning
Method: Randomized controlled trial in 5xFAD mice (n=15/group), stereological counting of synaptic puncta in somatosensory cortex, blinded analysis
IF we perform longitudinal in vivo two-photon microscopy to monitor dendritic spine turnover in Trem2^R47H knock-in mice crossed with Thy1-YFP reporters following a 4-week regimen of TREM2-activating nanobodies (0.5mg/kg, biweekly), THEN we will observe increased spine elimination rate (≥30% elevation) and unchanged spine formation rate, resulting in net spine loss, within 6 weeks of treatment initiation.
pendingconf: 0.58
Expected outcome: Spine elimination rate increases to ≥0.05eliminations/hour with unchanged spine formation rate (<0.05/hour), yielding net spine density reduction of 15-25%
Falsified by: Spine elimination rate remains unchanged (<5% difference from baseline) or spine formation rate increases significantly, indicating TREM2 activation does not selectively enhance pruning
Method: Longitudinal two-photon imaging of somatosensory cortex dendrites in Trem2^R47H mice (n=12/group), twice-weekly imaging over 6 weeks